Skip to main content
Equibles

ROYAL LONDON ASSET MANAGEMENT LTD

Position in RPRX — Royalty Pharma plc

CIK 863748 UNITED KINGDOM, X0
Back to RPRX Full portfolio

Position in RPRX

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$242,199,691
+$59,512,998 QoQ
Shares Held
4,319,595
+13.4% QoQ
Ownership
0.751%
of shares outstanding
% of Portfolio
0.44%
of 13F equity value
Holder Rank
#15
of 646 holders
Holding Since
Mar 2021
22 quarters on record
Voting authority Sole 96% Shared 0% None 4%

Common Shares in RPRX Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

ROYAL LONDON ASSET MANAGEMENT LTD holds $597,315,774 across 9 Biotechnology names. RPRX ranks #1 (40.5% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 RPRX
Royalty Pharma plc
This page 		4,319,595 $242,199,691
2 HALO
Halozyme Therapeutics, Inc.
 1,810,815 $141,732,490
3 VRTX
Vertex Pharmaceuticals Inc / Ma
 241,280 $119,851,014
4 ALNY
Alnylam Pharmaceuticals, Inc.
 213,589 $64,296,696
5 INCY
Incyte Corp
 190,323 $21,575,015
6 REGN
Regeneron Pharmaceuticals, Inc.
 3,887 $2,423,699
7 INSM
INSMED Inc
 22,116 $2,358,007
8 LEGN
Legend Biotech Corp
 75,000 $2,166,000

All Filings in RPRX

Export CSV
22 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $242,199,691 4,319,595
2026-03-31 $182,686,693 3,808,353
2025-12-31 $6,942,951 179,683
2025-09-30 $6,296,456 178,471
2025-06-30 $6,430,310 178,471
2025-03-31 $5,651,464 181,544
2024-12-31 $4,532,999 177,695
2024-09-30 $4,531,605 160,184
2024-06-30 $4,110,476 155,877
2024-03-31 $10,312,589 339,565
2023-12-31 $9,039,249 321,796
2023-09-30 $8,644,469 318,514
2023-06-30 $8,176,532 265,990
2023-03-31 $5,131,536 142,424
2022-12-31 $5,043,581 127,621
2022-09-30 $4,821,961 120,009
2022-06-30 $5,212,455 123,988
2022-03-31 $4,830,572 123,988
2021-12-31 $4,705,647 118,084
2021-09-30 $4,267,555 118,084
2021-06-30 $4,840,263 118,084
2021-03-31 $5,150,824 118,084